ALKS vs JAZZ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JAZZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALKS and JAZZ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALKS and JAZZ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution.

Full ALKS guide

Jazz Pharmaceuticals is an Ireland-domiciled specialty biopharmaceutical company that develops and markets treatments in neuroscience and oncology. Its largest products are Xywav and Xyrem (low-sodium and legacy oxybates for narcolepsy and idiopathic hypersomnia) and Epidiolex/Epidyolex (a cannabidiol treatment for rare epilepsies), which together anchor a neuroscience portfolio generating several billion dollars a year. Jazz has expanded aggressively into oncology through Zepzelca (small cell lung cancer), Rylaze (pediatric leukemia), Ziihera/zanidatamab (a HER2-directed bispecific antibody) and Modeyso (dordaviprone for diffuse glioma, added via the 2025 Chimerix acquisition).

Full JAZZ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALKS drivers: Orexin pipeline optionality; Cash-generative commercial base.
• JAZZ drivers: Sleep franchise durability; Oncology pivot and Ziihera.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. For JAZZ, jazz is concentrated in a few large products, so any acceleration of generic or branded competition against Xywav or Epidiolex could pressure revenue and the stock.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALKS if you believe its drivers more; JAZZ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALKS and JAZZ guides.

ALKS. First-quarter 2026 revenue of roughly $393 million rose about 28% year over year, helped by product growth and the newly consolidated Lumryz, though the quarter showed a GAAP net loss partly reflecting Avadel deal costs. Adjusted EBITDA of around $80 million underscores the underlying profitability of the marketed portfolio. At an approximately $8.5 billion market cap on roughly $1.5 billion of trailing revenue, the market is pricing in meaningful pipeline value beyond the current product base.

JAZZ. Jazz combines several billion dollars of high-margin drug revenue with strong non-GAAP earnings, yet trades at a comparatively low multiple relative to those profits. The gap reflects investor concern about patent cliffs and competition rather than current profitability. Net debt of roughly $3 billion means capital allocation and acquisition discipline matter to the equity story.

Headline figures (approximate, July 2026): ALKS shows revenue (ttm) ~$1.5B, q1 2026 revenue ~$393M (+28% YoY), q1 2026 adj. ebitda ~$80M, q1 2026 gaap net loss ~$(67)M; JAZZ shows revenue (ttm) ~$4.3B, 2026 revenue guidance ~$4.25B to $4.5B, q1 2026 revenue ~$1.07B (up ~19% YoY), market cap ~$15B.

ALKS and JAZZ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALKS and JAZZ exposure against your real portfolio. It is not an investment adviser.